Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study and a Phase 2a program planned for 2021.
Company profile
Ticker
ALNAQ
Exchange
Website
CEO
Louis Brenner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ALNAQ stock data
Latest filings (excl ownership)
SEC STAFF ACTION
SEC staff action: Order
12 Jun 23
NT 10-Q
Notice of late quarterly filing
14 Nov 22
25-NSE
Exchange delisting
14 Sep 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Sep 22
8-K
Termination of a Material Definitive Agreement
2 Sep 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Aug 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Other Events
11 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
4 Aug 22
DEFA14A
Additional proxy soliciting materials
13 Jul 22
Latest ownership filings
SC 13G/A
Third Rock Ventures II, L.P.
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 22
4
Richard D Katz
2 Feb 22
4
LOUIS MD BRENNER
2 Feb 22
SC 13G/A
Frazier Healthcare VI, L.P.
28 Jan 22
SC 13G/A
HIRSCHMAN ORIN
25 Jan 22
4
LOUIS MD BRENNER
17 Nov 21
4
Alexey L Margolin
4 Jun 21
4
Robert Alexander
4 Jun 21
4
Allene M. Diaz
4 Jun 21
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.59 mm | 6.59 mm | 6.59 mm | 6.59 mm | 6.59 mm | 6.59 mm |
Cash burn (monthly) | 768.67 k | 1.67 mm | 2.31 mm | 3.42 mm | 1.52 mm | 4.07 mm |
Cash used (since last report) | 16.76 mm | 36.45 mm | 50.31 mm | 74.54 mm | 33.11 mm | 88.79 mm |
Cash remaining | -10.17 mm | -29.87 mm | -43.72 mm | -67.95 mm | -26.52 mm | -82.20 mm |
Runway (months of cash) | -13.2 | -17.9 | -18.9 | -19.9 | -17.5 | -20.2 |
Institutional ownership, Q1 2022
7.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 4 |
Closed positions | 8 |
Increased positions | 6 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 2.84 mm |
Total shares | 9.70 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TRV GP Ii | 2.79 mm | $645.00 k |
Vanguard | 2.58 mm | $597.00 k |
Frazier Healthcare VI | 1.65 mm | $978.00 k |
Frazier Management | 1.02 mm | $236.00 k |
Geode Capital Management | 335.57 k | $77.00 k |
BLK Blackrock | 258.92 k | $61.00 k |
STT State Street | 205.06 k | $47.00 k |
Kestra Advisory Services | 173.16 k | $40.00 k |
Bridgeway Capital Management | 124.20 k | $29.00 k |
FMR | 106.18 k | $25.00 k |